



Commercial/Healthcare Exchange PA Criteria

Effective: February 9, 2023

Prior Authorization: Krazati

Products Affected: Krazati™ (adagrasib) oral tablets

Medication Description: KRAZATI is an irreversible inhibitor of KRAS G12C that covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state that prevents downstream signaling without affecting wild-type KRAS protein. Adagrasib inhibits tumor cell growth and viability in cells harboring KRAS G12C mutations and results in tumor regression in KRAS G12C-mutated tumor xenograft models with minimal off-target activity.

Covered Uses: Krazati is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

Exclusion Criteria: None

Required Medical Information:

1. Diagnosis
2. Medical History

Prescriber Restriction: None

Age Restriction: 18 years of age and older

Coverage Duration: Approve for 1 year

Other Criteria:

Initial Approval Criteria

1. **Non-Small Cell Lung Cancer (NSCLC).** Approve for 1 year if the patient meets the following criteria (A, B, **and** C):

- A. Patient is \geq 18 years of age; **AND**
- B. Patient has KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an approved test; **AND**
- C. Patient has been previously treated with at least one systemic regimen.

Note: Examples of systemic regimens include those containing one or more of the following products: Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Tecentriq (atezolizumab intravenous infusion), Alimta (pemetrexed intravenous infusion), Yervoy (ipilimumab intravenous infusion), Abraxane (albumin-bound paclitaxel intravenous infusion), bevacizumab, cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine.

Quantity Limit: 180 Tablet/30 Days

2/2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Page 1 of 2



References:

1. Krazati™ tablets [prescribing information]. San Diego, CA: Mirati Therapeutics; December 2022.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	02/09/2023